- Trial phase
- Phase 2a (discontinued after failure)
- Time to market
- SION-719 has been discontinued and will not reach the market. The company's remaining pipeline candidate (SION-451 + SION-2222) is expected to enter Phase 2a in Q1 2027, with potential approval years away if successful.
- Why 2/10
- SION-719 has already failed its Phase 2a trial and been discontinued. There is no upcoming catalyst for this specific drug. The company has pivoted to other pipeline assets (SION-451 + SION-2222), whose Phase 2a trial is expected to begin in Q1 2027. ImpactScore is 2 because the drug is a failed/discontinued program with no scheduled binary catalyst.
SION-719 has been discontinued after failing its Phase 2a endpoint. The next catalyst for Sionna is the AscenSION CF Phase 2a trial of SION-451 + SION-2222, expected to initiate in Q1 2027. Q3 2026 earnings were just reported on Nov 10, 2026, showing $249.8M cash and a $32.4M quarterly loss. Multiple securities fraud investigations are ongoing.
Price Chart
Executive Summary
SION-719 is an NBD1 stabilizer being developed by Sionna Therapeutics (NASDAQ: SION) as an add-on treatment for cystic fibrosis. The drug failed its Phase 2a proof-of-concept trial (PreciSION CF) in August 2026, missing the key sweat chloride endpoint (p=0.7). The stock crashed approximately 92% on the news. Sionna has discontinued the SION-719 program, cut 46% of its workforce, and is pivoting to a different pipeline combination (SION-451 + SION-2222). Multiple securities fraud investigations have been launched. The company reported $249.8M in cash as of Q3 2026, funding operations into 2029.
How It Works
SION-719 is an NBD1 (Nucleotide Binding Domain 1) stabilizer, a type of small molecule designed to fix a specific part of the CFTR protein that is defective in cystic fibrosis. The goal was to restore the protein's function so it can properly move salt and water in and out of cells, improving lung function. It was being tested as an add-on to Trikafta, the current standard-of-care CF treatment from Vertex Pharmaceuticals.
Trial Status
The Phase 2a PreciSION CF trial (NCT07108153) enrolled 15 adult CF patients homozygous for F508del on stable Trikafta. It completed on June 25, 2026. Topline results reported August 10, 2026 showed the drug failed to meet its key activity endpoint: -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7). The company is not advancing SION-719 as an add-on to standard of care.
The Two-Sided Case
Upcoming Catalysts
- None for SION-719 specifically (program discontinued). For Sionna: AscenSION CF Phase 2a trial of SION-451 + SION-2222 expected to initiate Q1 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sionna Therapeutics, Inc. PRESS-RELEASE SION ·Originating report